Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting
15 oct. 2024 11h48 HE
|
Trethera Corporation
LOS ANGELES, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development
09 sept. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting
05 août 2024 12h28 HE
|
Osteal Therapeutics
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
24 juil. 2024 08h05 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
16 juil. 2024 09h00 HE
|
Flag Therapeutics, Inc.
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
16 juil. 2024 08h37 HE
|
Trethera Corporation
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Rare Diseases Global Market Report 2024-2034: Robust Pipeline by Major Players and Increasing Number of Drug Approvals
02 juil. 2024 04h01 HE
|
Research and Markets
Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Rare Diseases Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Rare Diseases Market is forecast to...
Registrations Open for the 2024 Orphan Drugs and Rare Diseases Conference - Boston, MA, United States - October 17-18th, 2024
28 juin 2024 10h26 HE
|
Research and Markets
Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Orphan Drugs and Rare Diseases" conference has been added to ResearchAndMarkets.com's offering. The 2 day Orphan Drugs and Rare Diseases Conference...
Global $38.9 Billion Medical Food Market by Category, Type, Form, Distribution Channel, Application, and Region - Forecast to 2030
21 juin 2024 09h15 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Medical Food Market 2024-2030" report has been added to ResearchAndMarkets.com's offering.The Medical Food Market size was estimated at USD...
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
11 juin 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.